The anti‐tumor efficiency of liposome@siS100A5 was tested in the following four groups: (1) liposome + IgG2a isotype, (2) liposome@siS100A5 + IgG2a isotype, (3) liposome + anti‐PD‐1, (4) liposome@siS100A5 + anti‐PD‐1. This evidence concerns the gene PDCD1 and neoplasm.